[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spasticity-muscle\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spasticity-muscle":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,41,91,117,143,170,196,219,241,271,295,320,345],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100456672","does-eswt-with-bonta-treatment-improve-outcomes-when-compared-to-standard-management-for-upper-limb-spasticity-patient-100456672",false,"NCT05226637","Does ESWT With BoNTA Treatment Improve Outcomes When Compared to Standard Management for Upper Limb Spasticity Patient.","Does Extra-corporeal Shock Wave Therapy Combined With Botulinum Toxin Type A Treatment Improve Clinical and Patient Reported Outcomes When Compared to Standard Management (BoNTA) in Patients With Upper Limb Spasticity of Cerebral Origin?","Inclusion Criteria:\n\n* People with upper limb Spasticity of Cerebral Origin, including but not limited to:\n* Acquired brain injury (of at least 1 year following the event);\n* Stroke;\n* Cerebral Palsy (CP);\n* Male and females over 18 years of age.\n* Female subjects must either be post-menopausal, sterilized (at least 12 months post menses) or be consistently using a highly effective method of birth control such as a sterilized partner, oral\u002Fimplanted\u002Finjected contraception or abstinence of sexual activity and be willing to provide a pregnancy test as the safe use of ESWT during pregnancy has not been demonstrated.\n* Being naive to shockwave therapy;\n* Spasticity as defined by Modified Ashworth Scale (MAS) score of 2 in a functional or non-functional upper limb affecting the target joint, which for the purpose of the study will be the elbow;\n* Willingness to participate and provide written consent;\n* Have the cognitive capacity to answers simple questionnaires;\n* Either already receiving treatment with BoNTA and having been 'washed out' for a period of three months, or intends to begin 'standard treatment with BoNTA to an affected arm with target joint involvement.\n* Standard treatment in the context of the study will include, in addition to any other therapies, focal treatment with Botulinum Neurotoxin Type A to treat the target joint.\n\nExclusion Criteria:\n\n* Known neurodegenerative disorder at the spinal level;\n* Known spinal cord lesion ;\n* Fixed contracture of target joint impeding assessment or MAS of 4;\n* Any demonstrated lower motor neuron damage to the affected limb;\n* Surgery received to affected arm that may affect assessment of the target joint;\n* Any changes in either oral or focally injected medications one month prior to screening to close out, that could influence any outcome measures;\n* Any changes in medication one month prior to screening to close out, for the treatment of depression as changes in patient affect may influence outcome measures;\n* Any changes in rehabilitation therapy throughout the study cycles;\n* Confirmed pregnancy. Safe use in this population remains unknown;\n* Nursing mothers. Safe use in this population remains unknown;\n* Female patients who are of childbearing age without adequate contraception and unwilling to take a pregnancy test;\n* Implanted electronic device\u002Fs. Kinetic energy in the same territory as an implanted device may adversely affect the device's function;\n* Patients taking Warfarin and have poorly controlled coagulopathy or an INR above 3 at the Point of Care. To avoid hematoma, compartment syndrome or other consequences of prolonged bleeding to treated area. This is also the same program criteria for injection with BoNTA. For this population INR will be determined (using the Coguchek XL device) prior to each treatment;\n* Any malignant diagnoses. Tissue disruption caused by the shockwave treatment may precipitate the liberation or shedding of cancer cells;\n* Any known infection, inflammatory process, open areas or acute undiagnosed swelling (acute being defined as 14 days or sooner) in the area treated to avoid worsening of any pre-existing condition;\n* Participation in any other concurrent study.","ALL","18 Years","99 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background Effective management of spasticity, a debilitating and challenging condition afflicting many recovering from and living with neurological conditions, may reduce long term consequences such as limb contracture, skin breakdown, compromised mobility, caregiver burden and discomfort. In rehabilitation, spasticity represents a significant barrier to successful rehabilitation outcomes. Effective spasticity management can increases the length of individual functional status, reduces equipment\u002Fcare needs, hospital admissions and extends the time people can stay safely at home, which would represent an economic benefit to the health system. Extra-corporeal Shock Wave Therapy (ESWT), an intense short energy wave delivered directly at the region of affected muscles has, in past randomized controlled studies, demonstrated positive outcomes for this population (spastic stroke population, TBI), on its own and as an adjunct to current modalities. In fact, one retrospective observational study demonstrated an increased efficacy of Toxin botulinum at 1 month when combined with ESWT. Where existing treatment options may be limited by coverage, access to delivery, complications and side effects, ESWT represents a potential to be a safe, low cost, efficacious alternative that can be administered by any trained clinician.\n\nAims The aims of this pilot study will be to explore the hypothesis that adding ESWT to Botulinum Neurotoxin A (BoNTA) in spasticity post-stroke (TBI)will demonstrate greater clinical and patient reported outcomes compared to standard treatment with BoNTA alone, a comparison only once previously studied.\n\nMethods Incorporating randomization and placebo control (n= 20 in each arm), this patient-centric study will examine treatment goals and holistic perception of benefit after the treatment experience. We will use patient reported outcomes at baseline and at defined intervals after intervention. We will test our hypothesis using clinical and patient reported scales, such as the patient reported numeric rating scale (NRS) and goniometric range for spasticity as our primary outcome in conjunction with measures of muscle stiffness, quality of life, feasibility and acceptability of the protocol to help inform future study direction.",[27],"Spasticity, Muscle","RECRUITING","2026-04-07",{"date":31,"type":32},"2026-04-13","ACTUAL",{"date":34,"type":32},"2022-04-29",{"date":36,"type":21},"2026-12",{"name":38,"class":39},"University of Alberta","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":40},"100466506","hereditary-spastic-paraplegia-genomic-sequencing-initiative-hspseq-100466506","NCT05354622","Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)","Investigating the Genetic Basis of Hereditary Spastic Paraplegia","Inclusion Criteria:\n\n* Clinical diagnosis of progressive spasticity","1 Month","30 Years",{"count":51,"type":21},200,"5 Years","OBSERVATIONAL","The purpose of the HSP Sequencing Initiative is to better understand the role of genetics in hereditary spastic paraplegia (HSP) and related disorders. The HSPs are a group of more than 80 inherited neurological diseases that share the common feature of progressive spasticity. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability, with a combined prevalence of 2-5 cases per 100,000 individuals worldwide.\n\nIn childhood-onset forms, initial symptoms are often non-specific and many children may not receive a diagnosis until progressive features are recognized, often leading to a significant diagnostic delay. Genetic testing in children with spastic paraplegia is not yet standard practice. In this study, the investigators hope to identify genetic factors related to HSP. By identifying different genetic factors, the investigators hope that over time we can develop better treatments for sub-categories of HSP based on cause.",[56,57,58,27,59,60],"Hereditary Spastic Paraplegia","Neurodegenerative Diseases","Pediatric Disorder","Motor Neuron Disease","Movement Disorders",[56,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81],"Neurodegenerative disease","Spasticity","SPG3a","SPG4","SPG11","SPG15","SPG26","SPG47","SPG50","SPG51","SPG52","Complex hereditary spastic paraplegia","Early Onset hereditary spastic paraplegia","Movement disorder","Adaptor protein complex 4","Neurogenetic disorder","Genetic Disease","Muscle Spasticity","Neurodevelopmental disorders","Musculoskeletal Disease","2026-03-16",{"date":84,"type":32},"2026-03-18",{"date":86,"type":32},"2022-04-25",{"date":88,"type":21},"2027-04-29",{"name":90,"class":39},"Boston Children's Hospital",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100521487","radiosurgery-treatment-for-spasticity-associated-with-stroke-sci--cerebral-palsy-100521487","NCT06070233","Radiosurgery Treatment for Spasticity Associated With Stroke, SCI & Cerebral Palsy","A Randomized, Sham Controlled Trial of Dorsal Root Rhizotomy Stereotactic Radiosurgery Versus Standard of Care for Spasticity Associated With Stroke, Spinal Cord Injury & Cerebral Palsy","SPASM","Inclusion Criteria:\n\n* Chronic spasticity refractory to medical management or in a patient who cannot receive appropriate medical management mediated by one or more spinal nerve roots\n* Age \\> 16 (if under 18, patients parents must sign consent).\n\nExclusion Criteria:\n\n* Inability to lie supine for simulation \\& treatment\n* Inability to visualize the target nerve on either CT or MRI imaging\n* Patients with confirmed pregnancy (all women of child-bearing age with intact uterus \\& ovaries will be required to undergo a pregnancy test prior to simulation)","16 Years",{"count":101,"type":21},22,[24],"A scientific study is being done to test a special treatment for people who have spasticity or tight muscles. This treatment is called \"stereotactic radiosurgery dorsal rhizotomy.\" It uses very accurate beams of radiation to target certain nerves in the back to help loosen up the muscles. In this study, people are put into two groups by chance: one group gets the real treatment, and the other group gets a \"fake\" treatment that doesn't do anything. This fake treatment is called a \"sham.\" Doing this helps make sure the study is fair and the results are true. After the people in the study get their treatment, the researchers will watch and see how they do. They will check if their muscles are less stiff and if they have any side effects. By looking at the results from both groups, the researchers can find out if the special treatment really helps people with spasticity. Patients who got the \"fake\" treatment will be eligible to receive the \"real\" treatment after 6 months.",[105,106,27],"Spasticity as Sequela of Stroke","Spastic Cerebral Palsy","2025-12-18",{"date":109,"type":32},"2025-12-19",{"date":111,"type":32},"2023-10-12",{"date":113,"type":21},"2026-12-31",{"name":115,"class":39},"Ohio State University",2,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":141,"locationsCount":116},"100446509","operant-conditioning-of-spinal-reflexes-training-system--reflex-operant-down-conditioning-100446509","NCT05094362","Operant Conditioning of Spinal Reflexes Training System--Reflex Operant Down Conditioning","Operant Conditioning of Spinal Reflexes to Enhance Motor Function Recovery After Spinal Cord Injury","Inclusion Criteria:\n\n1. a clinically stable spinal cord injury (above T11) that occurred at least one year previously\n2. the ability to ambulate at least 10 m with or without an assistive device (i.e., walker, crutches, or cane, not parallel bars) within 100 sec (those with 10-meter walking time \\>100 sec are excluded because it is unlikely that they are able to participate in and complete our planned locomotion evaluation procedures)\n3. clinical signs of spasticity in the plantarflexor muscles at least unilaterally (i.e., hyperreactivity to Achilles tendon tap, and increased muscle tone, score \\>1 on Modified Ashworth scale)\n4. spastic hyperreflexia reflected in exaggerated H-reflex\n5. functionally and medically stable for at least 3 months\n6. medical clearance to participate\n7. reasonable expectation that current medications (including antispasticity medication such as baclofen, diazepam, and tizanidine) will not change over the conditioning period. Each participant's medication and dosage will be monitored and recorded throughout the study. Once enrolled, the subject will remain enrolled even if medication changes. (Because only neurologically stable subjects will enter this study, medication changes will be unlikely.)\n\nExclusion Criteria:\n\n1. motoneuron injury;\n2. a cardiac condition (history of myocardial infarct, pacemaker use, etc.)\n3. an unstable medical condition\n4. a pre-existing or confounding neurological condition (e.g., history of Multiple Sclerosis (MS), Traumatic Brain Injury (TBI), Stroke, Parkinson's disease)\n5. a condition that prevents lower extremity mobility testing or weight bearing (e.g. fracture, severe sprain\u002Fstrain, botox muscular injection) (orthotic knee hyperextension is not excluded; in severe cases of knee hyperextension, the brace can be worn during the study sessions)\n6. a cognitive impairment that precludes giving informed consent (e.g., severe intellectual disability)\n7. use of a functional electrical stimulation (FES) foot-drop stimulator or an FES bicycle on a daily basis (FES applied to the arm is acceptable)\n8. deep vein thrombosis within the past 6 months\n9. depression (due to potential interference of anti-depressant medication with the intervention and possible reduced participation reliability)\n10. pregnancy (due to expected changes in weight and posture and potentially unstable medical condition).",{"count":125,"type":21},25,[24],"The purpose of this study is to validate the capacity of a reflex training system to change the size of the targeted reflex. For this, the researchers are recruiting 25 individuals with chronic incomplete SCI who have spasticity in the leg to participate in the reflex training procedure. The study involves approximately 45 visits with a total study duration of about 6 months.",[129,130,131,27],"Spinal Cord Injuries","Neurological Injury","Paralysis",[133,134],"Neuroplasticity","Spinal Reflex","2025-09-05",{"date":137,"type":32},"2025-09-09",{"date":139,"type":32},"2023-08-23",{"date":113,"type":21},{"name":142,"class":39},"Medical University of South Carolina",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":40},"100544176","flexwave-trial-efficacy-of-extracorporeal-shock-wave-therapy-in-post-stroke-upper-limb-spasticity-100544176","NCT06365476","FlexWave Trial: Efficacy of Extracorporeal Shock Wave Therapy in Post-Stroke Upper Limb Spasticity","Effects of Extracorporeal Shock Wave for Upper Limb Flexor Spasticity in Stroke Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Individuals aged 18 years or older with unilateral cerebral stroke.\n* Wrist and finger flexor muscle tone with a score greater than 1 on the Modified Ashworth Scale.\n* Stable medical condition and vital signs.\n* Conscious and able to comply with instructions.\n\nExclusion Criteria:\n\n* History of more than one stroke, traumatic brain injury, or cerebral neoplasm.\n* Coexisting central nervous system disorders (e.g., spinal cord injury, Parkinson's disease) or other musculoskeletal diseases affecting muscle tone assessment.\n* Contraindications for shockwave intervention, such as malignancies, coagulopathies, local infections, or use of cardiac pacemakers.\n* Undergone shockwave therapy or botulinum toxin injections for post-stroke spasticity in the past three months.\n* Cognitive, consciousness, or language impairments preventing participation in the intervention or functional assessments.",{"count":20,"type":21},[24],"Extracorporeal shock wave therapy (ESWT) has emerged as an effective therapeutic intervention for addressing post-stroke limb spasticity. This research aims to explore the therapeutic implications of focused ESWT for wrist and finger flexor muscles in patients suffering from post-stroke upper limb spasticity.",[154,27],"Stroke",[156,157,158,159,160],"stroke","spasticity","shock wave","wrist","finger","2025-07-27",{"date":163,"type":32},"2025-07-29",{"date":165,"type":32},"2024-04-15",{"date":167,"type":21},"2027-04-15",{"name":169,"class":39},"National Taiwan University Hospital",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":177,"maxAge":17,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":40},"100524469","investgaton-of-the-effectveness-of-the-moll-sut-in-chldren-wth-ambulatory-cerebral-palsy-100524469","NCT06109129","Investıgatıon Of The Effectıveness Of The Mollıı Suıt In Chıldren Wıth Ambulatory Cerebral Palsy","Investıgatıon Of The Effectıveness Of The Mollıı Suıt In Chıldren Wıth Ambulatory Cerebral Palsy: A Double-Blınd Randomızed Controlled Study","Inclusion Criteria:\n\n* Being a voluntary participant in the study,\n* Having a diagnosis of spastic CP,\n* Being between 1-3 on the Gross Motor Classification System (GMFCS),\n* Being between the ages of 4 and 18,\n* Being able to express pain and discomfort\n\nExclusion Criteria:\n\n* Being between 4-5 on Gross Motor Classification System (GMFCS)\n* Having Botolunim Toxin A application before 3 months\n* Having a surgical intervention before 6 months\n* Having a shunt or an invasive medical pump (baclofen, insulin, etc.)","4 Years",{"count":179,"type":21},32,[24],"Cerebral Palsy (CP) is the most common developmental disorder in childhood. Individuals' independence in daily living activities and participation in education, games, social and community activities are restricted. Technology applications in the field of rehabilitation are gaining momentum. EXOPULSE Mollii Suit method, one of the newest rehabilitation technology products, is a non-invasive neuromodulation approach with a garment that covers the whole body and electrodes placed inside. Designed to improve motor function by reducing spasticity and pain, the method is based on the principle of reciprocal inhibition, which occurs by stimulating the antagonist of a spastic muscle at low frequencies and intensities. Therefore, the aim of our study is to examine the effectiveness of the Mollii Suit application on gross and fine motor function, spasticity severity, balance, walking, selective motor control, postural control, daily living activities, quality of life, pain and sleep quality in individuals with ambulatory spastic CP.",[183,27],"Cerebral Palsy",[183,185,63,186],"Rehabilitation Technology","Electrotherapy","2025-07-08",{"date":189,"type":32},"2025-07-11",{"date":191,"type":32},"2023-11-05",{"date":193,"type":21},"2025-11-05",{"name":195,"class":39},"Kastamonu University",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":116},"100537699","study-of-brain-spinal-cord-neural-connectivity-in-spasticity-100537699","NCT06281223","Study of Brain-spinal Cord Neural Connectivity in Spasticity","MOVE","Inclusion Criteria:\n\n* Patients aged 3 to 17 years included\n* scheduled for selective rhizotomy surgery\n* Having received informed consent to participate in the study (written consent from both parents)\n* Affiliated or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Contraindications to selective rhizotomy\n* History of epilepsy\n* Known neurological and\u002For psychiatric disorders with past and\u002For current medical treatment, or drug addiction\n* Patient under legal protection\n* Pregnant or breast-feeding women","3 Years","17 Years",{"count":206,"type":21},50,"Little is known about the peripheral and central mechanisms of action of selective dorsal rhizotomy surgery for the treatment of spasticity. A better understanding of these mechanisms will enable us to improve the surgical procedure. This will require cortico-medullo-radiculo-muscular recordings never before performed and published in the literature, and the identification of variations in connectivity correlated with the clinic.",[27],"2025-06-06",{"date":211,"type":32},"2025-06-11",{"date":213,"type":32},"2024-02-26",{"date":215,"type":21},"2026-05",{"name":217,"class":218},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":40},"100538421","vibrotactile-coordinated-reset-for-spasticity-after-spinal-cord-injury-100538421","NCT06290609","Vibrotactile Coordinated Reset for Spasticity After Spinal Cord Injury","Control of Incomplete Spinal Cord Injury-Related Spasticity by Means of Vibrotactile Coordinated Reset Fingertip Stimulation","Inclusion Criteria:\n\n1. Age at the time of enrollment: Any adult ages 18 and over\n2. Spinal Cord Injury: ASIA C or D injury at level C1-T1\n3. Duration of incomplete spinal cord injury minimum 1 years clinical\u002Ffundamental\n4. Spasticity with a of MAS score \\>3 present in upper extremities.\n5. Fluent in English\n6. If patient is on medication that affects brain function or alters EEG activity, the patient must feel comfortable going off this medication prior to EEG recording.\n7. Appropriate social support if required during an off-medication state.\n8. Comfortable with technology; can use a computer, check email, and access the internet; can initiate and engage in a virtual meeting for training and monitoring purposes.\n9. Feels comfortable going off certain spasticity related medication during in-person study visits\n10. Lives in the United States\n\nExclusion Criteria:\n\n1. Sensory deficits in palma manus resulting in missing inter digit discrimination of the fingertips.\n2. Any significant neuro-psychiatric problems, including acute confusional state, ongoing psychosis, or suicidal tendencies.\n3. Any current drug or alcohol abuse.\n4. Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. Any other trial participation should be approved by the Principal Investigators.\n5. Pregnancy, breast-feeding or wanting to become pregnant.\n6. Physical limitations unrelated to spasticity that would affect motor ratings.\n7. Craniotomy\n8. Brain surgery\n9. Patient is unable to communicate properly with staff (i.e., severe speech problems)\n10. Medications that may affect relevant synaptic plasticity\n11. Concurrent Botox treatment\n12. A type of hairstyle that would impede the use of an EEG cap.",{"count":227,"type":21},30,[24],"The purpose of our study is to evaluate vibrotactile Coordinated Reset (vCR) and its effects on spasticity symptoms in incomplete spinal cord injured patients. vCR will be administered with a device called the Stanford CR Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments such as oral baclofen and or deep brain stimulation. Patients will be followed for three months and will be asked to come to the lab for clinical testing 4 times during this period. A total of 30 patients will be included in the study.",[27,129],"NOT_YET_RECRUITING","2025-05-12",{"date":234,"type":32},"2025-05-15",{"date":236,"type":21},"2026-03-15",{"date":238,"type":21},"2028-06-15",{"name":240,"class":39},"Stanford University",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":248,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":22,"phases":252,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":40},"100479069","phase-1-melpida-recombinant-adeno-associated-virus-serotype-9-encoding-a-codon-optimized-human-ap4m1-transgene-hap4m1opt-100479069","NCT05518188","Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)","A Phase 1\u002F2 Open-label Intrathecal Administration of MELPIDA to Determine Its Safety and Efficacy for Patients with Spastic Paraplegia Type 50 (SPG50) Caused by Mutation in the AP4M1 Gene.","Inclusion Criteria:\n\n1. Age 4 months-10 years old\n2. Confirmed diagnosis of SPG50 disease by:\n\n   1. Genomic DNA mutation analysis demonstrating homozygous or compound heterozygous, confirmed pathogenic variants in the AP4M1 gene\n   2. Clinical history or examination features consistent with SPG50 and that include neurologic dysfunction\n3. Parent\u002Flegal guardian willing to provide written informed consent for their child prior to participation in the study\n4. Subject able to comply with all protocol requirements and procedures\n5. Ability to stand for more than 5 seconds OR\n6. Ability to take 5 steps independently or with a walker OR\n7. Modified Ashworth Scale score 2 or below (Ankles).\n\nExclusion Criteria:\n\n1. Inability to participate in study procedures (as determined by the site investigator)\n2. Presence of a concomitant medical condition that precludes lumbar puncture (LP) or use of anesthetics\n3. History of bleeding disorder or any other medical condition or circumstance in which lumbar puncture is contraindicated according to local institutional policy\n4. Inability to be safely sedated in the opinion of the clinical anesthesiologist\n5. Active infection, at the time of dosing, based on clinical observations\n6. Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer\n7. Inability of the patient to undergo MRI according to local institutional policy\n8. Inability of the patient to undergo any other procedure required in this study\n9. The presence of significant non-SPG50 related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study\n10. Have received an investigational drug within 30 days prior to screening or plan to receive an investigational drug (other than gene therapy) during the study.\n11. Enrollment and participation in another interventional clinical trial\n12. Contraindication to MELPIDA or any of its ingredients\n13. Contraindication to any of the immune suppression medications used in this study\n14. Clinically significant abnormal laboratory values (GGT, ALT, and AST, or total bilirubin \\> 3 × ULN, creatinine ≥ 1.5 mg\u002FdL, hemoglobin \\[Hgb\\] \\< 6 or \\> 20 g\u002FdL; white blood cell \\[WBC\\] \\> 20,000 per cmm) prior to gene replacement therapy.","4 Months","10 Years",{"count":251,"type":21},4,[253,254],"PHASE1","PHASE2","MELPIDA is proposed for the treatment of subjects with SPG50 and targets neuronal cells to deliver a fully functional human AP4M1 cDNA copy via intrathecal injection to counter the associated neuronal loss. Outcomes will evaluate the safety and tolerability of a single dose of MELPIDA, which will be measured by the treatment-associated adverse events (AEs) and serious adverse events (SAEs). Secondarily, the trial will explore efficacy in terms of disease burden assessments.",[27,257,258,259,70,260],"Microcephaly","Intellectual Deficiency","Growth Retardation","Spastic Paraplegia","2024-10-04",{"date":263,"type":32},"2024-10-08",{"date":265,"type":32},"2023-02-15",{"date":267,"type":21},"2030-10-01",{"name":269,"class":270},"Elpida Therapeutics SPC","INDUSTRY",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":40},"100558174","extracorporeal-shock-wave-therapy-on-spastic-equinus-foot-in-stroke-patients-100558174","NCT06547684","Extracorporeal Shock Wave Therapy on Spastic Equinus Foot in Stroke Patients","Effects of Focused Extracorporeal Shock Wave Therapy on Spastic Equinus Foot in Stroke Patients: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age greater than 18 years old\n* Time from stroke (ischemic o hemorrhagic) onset of at least 6 months\n* Spastic equinus foot: triceps surae tone grade at least 1+ on the MAS score\n* Ability to walk alone with or without aids\n\nExclusion Criteria:\n\n* Fixed ankle joint contracture\n* Severe medical problems\n* Treatment of the affected leg with botulinum toxin in the las 6 months\n* Cognitive impairment",{"count":279,"type":21},60,[24],"The goal of this study is to evaluate long term effects of focused extracorporeal shock wave therapy (fESWT) on triceps surae spasticity in stroke patients according to the number of sessions applied.\n\nHypothesis: 3 sessions of fESWT on equinus foot in stroke patients improve spasticity and functionality for longer term than 1 session of fESWT.",[154,283,27],"Equinus Deformity",[154,283,285],"Extracorporeal Shock Wave Therapy","2024-09-07",{"date":288,"type":32},"2024-09-19",{"date":290,"type":32},"2020-08-28",{"date":292,"type":21},"2025-10-31",{"name":294,"class":39},"Teresa Mateu Campos",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":303,"sex":16,"minAge":17,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100557026","identification-of-sodium-channel-fragments-as-serum-biomarkers-of-a-traumatic-central-nervous-system-injury-100557026","NCT06532760","Identification of Sodium Channel Fragments as Serum Biomarkers of a Traumatic Central Nervous System Injury","Identification Des Fragments de Canaux Sodiques Comme Biomarqueurs sériques d'Une lésion Traumatique du système Nerveux Central","SpasT-SCI-T","healthy volonteers group: Inclusion Criteria\n\n* Male or Female\n* Age 18 to 75\n* free of central or peripheral nervous system trauma\n* Having given free and informed consent\n* Beneficiary of or affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Person under guardianship or curatorship\n* Diagnosis of a neurological disorder\n* Diagnosis of a psychiatric disorder\n* Diagnosis of a neurodegenerative disease\n\nSpinal Cord injury patients group:\n\nInclusion Criteria:- Male or female\n\n* Aged 18 to 75\n* Beneficiary of or affiliated to a social security scheme\n* Having suffered within 6 hours a trauma with an acute LME confirmed according to the following characteristics:\n* Lesion located at C4-T12 level and radiologically documented (CT scan and\u002For spinal MRI performed within 6 hours)\n* Complete or incomplete according to the American Spinal Injury Association impairment scale (ASIA A to D)\n* Signed consent for emergency and continuation of study\n\nExclusion criteria:\n\n* Pregnant or breast-feeding patient\n* Absence of consent from the volunteer or his\u002Fher trusted support person\n* Patient under guardianship or trusteeship\n* Brain injury due to cranioencephalic trauma with a Glasgow score of less than 14 on reassessment, associated with a cerebral CT scan of grade III or less on the Marshall classification\n* Presence of another neurological or mental disorder or neurodegenerative disease\n\nBrain injury patients Group:\n\nInclusion criteria:\n\n* Male or female\n* Aged 18 to 75\n* Have suffered a traumatic brain injury (TBI) with a proven acute brain injury according to the following characteristics:\n* Glasgow score less than 13 on admission without metabolic cause in the context of head trauma\n* Cerebral CT scan at least grade II according to Marshall classification\n* Absence of traumatic spinal lesion threatening the integrity of the spinal canal assessed by neuroradiological examination (CT and\u002For MRI)\n* Signed consent for emergency and continuation of study\n* ASIA E score\n\nExclusion criteria:\n\n* Pregnant or breast-feeding patient\n* Absence of consent from the volunteer or his\u002Fher trusted support person\n* Patient under guardianship\n* ASIA score A to D\n* Presence of another neurological or mental disorder or neurodegenerative disease",true,"75 Years",{"count":20,"type":21},[24],"Following spinal cord injury (SCI), 75% of patients develop spasticity of the limbs characterized by an increase in muscle tone causing severe pain. Currently, the diagnosis of spinal cord injury is based on clinical and radiological evaluation by CT and MRI, but there is no reliable biomarker capable of predicting the medium and long-term clinical course in terms of emergence and severity of spasticity and neurological recovery. Recently, pre-clinical models in rats have shown the presence of protein fragments from a cleavage of sodium channels in spinal cords below the level of injury. Other studies have also shown the presence of these fragments in the brain following a head injury. These fragments would be potentially useful as a biomarker of the SCI. The detection of sodium fragments would be potentially useful as a biomarker of a lesion of the central nervous system (spinal cord or brain) and of the severity of the spasticity in patients suffering from SCI. The main objective of this study is to detect the presence of sodium fragments in blood samples from patients with SCI from or brain injury. The secondary objectives will be to study the post-lesional \u002F injury kinetics of sodium fragments, to determine their diagnostic values in terms of the severity of the injury, and their prognostic values concerning the emergence of the spasticity in patients with SCI. An initial prospective cohort will include 40 people. The fragments of sodium channels will be measured in blood samples taken within 6 hours post-trauma, then 1, 3, 5 and 7 days post-trauma, as well as 3 and 6 months post-trauma. The overall expression of sodium fragments will be compared to that of healthy controls. Participants will be recruited in the acute care units of the AP-HM. Participants will be recruited from the main acute care units of the AP-HM. Post-traumatic follow-up assessments during their rehabilitation will be carried out at 3 and 6 months in the neurosurgery department of North Hospital from APHM.",[309,27,310],"Spinal Cord Injury","Brain Injuries","2024-07-31",{"date":313,"type":32},"2024-08-01",{"date":315,"type":21},"2024-10-01",{"date":317,"type":21},"2027-04-01",{"name":319,"class":39},"Assistance Publique Hopitaux De Marseille",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":16,"minAge":327,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":330,"conditions":331,"keywords":332,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":40},"100450588","obturator-cryoneurotomy-for-hip-adductor-spasticity-100450588","NCT05147441","Obturator Cryoneurotomy for Hip Adductor Spasticity","Evaluating the Efficacy of Obturator Cryoneurotomy for Hip Adductor Spasticity","Inclusion Criteria:\n\n1. Will have cryoneurotomy as part of their standard treatment for spastic hip adductors in VGH spasticity multidisciplinary clinic.\n2. Are at least 12 years of age at the time of the procedure.\n3. Have the ability to attend testing sessions, comply with testing protocols and provide written informed consent.\n4. Are able to understand and complete study-related questionnaires (must be able to understand and speak English or have access to an appropriate interpreter as judged by the investigator).\n\nExclusion Criteria:\n\n1. Have a history of previous nerve procedures such as chemical neurolysis with alcohol, cryoneurotomy, or any surgery to the obturator nerve.\n2. Have any other neurological pathology different from that responsible for the spasticity.","12 Years",{"count":329,"type":21},20,"The purpose of the study is to measure the effects of obturator nerve cryoneurotomy, on clinical measures in adult (ages 19+) and paediatric (ages 12-18) patients with hip adductor spasticity, who will receive this procedure as a part of their treatment based on the spasticity treatment available guidelines. The results will provide us valuable information like how long cryoneurotomy is effective, before regeneration happens",[27],[157,333,334,335],"Cryoneurotomy","Hip adductors","Range of motion","2024-06-12",{"date":338,"type":32},"2024-06-14",{"date":340,"type":32},"2021-08-10",{"date":342,"type":21},"2024-12",{"name":344,"class":39},"Vancouver Island Health Authority",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":16,"minAge":353,"maxAge":17,"enrollmentInfo":354,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":374},"100479098","the-muscle-in-cerebral-palsy-sarcomere-length-in-vivo-and-microscopic-characterization-of-biopsies-100479098","NCT05518565","The Muscle in Cerebral Palsy; Sarcomere Length in Vivo and Microscopic Characterization of Biopsies.","Exploration of the Length\u002FTension Relationship in Spastic Muscle in Vivo and Its Relation to the Muscle's Macromolecular Composition. The Results Are Related to Function Before and After Tendon Transfer\u002FTendon Lengthenings.","CPMuscleSL","Inclusion Criteria:\n\n* Celebral Palsy or Aquired Brain Injury\n\nExclusion Criteria:\n\n* Progressive neurological disease","2 Years",{"count":355,"type":21},150,"Cerebral palsy (CP) is a motor impairment due to a brain malformation or a brain lesion before the age of two. Spasticity, hypertonus in flexor muscles, dyscoordination and an impaired sensorimotor control are cardinal symptoms. The brain lesion is non-progressive, but the flexor muscles of the limbs will during adolescence become relatively shorter and shorter (contracted), forcing the joints into a progressively flexed position. This will worsen the positions of already paretic and malfunctioning arms and legs. Due to bending forces across the joints, bony malformations will occur, worsening the function even further. Currently, the initial treatment of choice is the use of braces, which diminishes the shortening somewhat, but eventually lengthenings of tendons and release of aponeuroses around the muscles often is needed, and transfers of wrist flexors to wrist extensors may improve wrist position. But the long-term results are unpredictable- how much does the muscle need to be lengthened? What muscles should be transferred for a better position of the wrist, and at what tension? A method to measure sarcomere length in vivo has been developed. The sarcomere, the distance between two striations, is the smallest contractile unit in the striated muscle. When, during surgery, a muscle fiber bundle is transilluminated with a low energy laser light, a diffraction pattern is formed. This diffraction pattern reflects the sarcomere length, and thereby an instant measure of how the stretch of the muscle is obtained. When performing tendon transfers of e.g. wrist flexors to wrist extensors, the setting of the tension of the transfer is arbitrary, and the long-term result is unpredictable. Laser diffraction measurements will give a guide to a precise setting of tension. It is known that there may be pathological changes in muscle in cerebral palsy that also will affect the long-term results of tendon lengthenings and transfers. In order to also take these changes into account, small muscle biopsies will be taken during the same surgeries. These will be examined with immuno-histochemical and biochemical techniques, gel-electrophoresis as well as electron microscopy.",[183,358,27],"Muscle Contracture",[183,360,361,362,363],"Muscle biopsy","Laser diffraction","Sarcomere Length","Muscle contracture","2022-08-25",{"date":366,"type":32},"2022-08-26",{"date":368,"type":32},"2002-01-15",{"date":370,"type":21},"2033-12-15",{"name":372,"class":373},"Eva Ponten","OTHER_GOV",3]